Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving Average of $4.54

Achieve Life Sciences, Inc. (NASDAQ:ACHV)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.54 and traded as high as $5.01. Achieve Life Sciences shares last traded at $4.73, with a volume of 212,749 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ACHV. Oppenheimer reduced their target price on shares of Achieve Life Sciences from $18.00 to $11.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Jonestrading began coverage on shares of Achieve Life Sciences in a research note on Wednesday, April 17th. They set a “buy” rating and a $20.00 target price for the company. Finally, Lake Street Capital reduced their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 5th.

Achieve Life Sciences Stock Performance

The firm has a fifty day moving average price of $4.92 and a 200 day moving average price of $4.54. The firm has a market capitalization of $162.43 million, a price-to-earnings ratio of -3.67 and a beta of 1.34.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). Research analysts predict that Achieve Life Sciences, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Achieve Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Madison Park Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences in the fourth quarter valued at $41,000. Virtu Financial LLC purchased a new stake in Achieve Life Sciences during the first quarter valued at about $59,000. Raymond James & Associates grew its position in Achieve Life Sciences by 6.0% during the fourth quarter. Raymond James & Associates now owns 154,829 shares of the biopharmaceutical company’s stock valued at $638,000 after acquiring an additional 8,729 shares during the period. CVI Holdings LLC purchased a new stake in Achieve Life Sciences during the first quarter valued at about $2,578,000. Finally, Vanguard Group Inc. grew its position in Achieve Life Sciences by 56.6% during the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock valued at $4,311,000 after acquiring an additional 342,731 shares during the period. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.